Nephrocare Health Services logo

Nephrocare Health Services

NEPHROPLUS NSE

Key Fundamentals

MicrocapHealthcare Service ProviderHealthcare Services
Market Cap
₹7,489 Cr
Volatility
Moderate
P/E Ratio
182.66
EBITDA
₹252 Cr
Return on Equity
6.88%
Debt to Equity
0.07
Book Value
₹111.03
52W High
₹769.75
52W Low
₹446

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 162% CAGR over last 5 years

Weaknesses

4
  • Stock is trading at 6.88 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 10.2% over last 3 years.
  • Company's cost of borrowing seems high

Growth Rate

Revenue Growth
32.93% higher than 3Y
Net Income Growth
14.46% lower than 3Y
Cash Flow Change
71.84% lower than 3Y
ROE
-40.12% lower than 3Y
ROCE
-11.39% lower than 3Y
EBITDA Margin (Avg.)
4.64% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 44d ago
AI opinion · based on fundamentals
Risk high

Nephrocare Health Services (NephroPlus) is a healthcare services company with a market cap of ₹6,798 Cr trading at a PE of 89.4x. The company has delivered strong revenue growth of 32% CAGR over 3 years and profit growth of 162% CAGR over 5 years, but carries a relatively low ROE of ~10% over 3 years and trades at 6.15x book value with zero dividend payout.

Bull Case 7
  • Exceptional profit growth of 162% CAGR over the last 5 years indicates strong operating leverage and scalability in the dialysis services business
  • Consistent revenue growth of 32% CAGR over 3 years and 28% over 5 years demonstrates sustained demand for nephrology services
  • Company is almost debt-free, significantly reducing financial risk and interest burden on the balance sheet
  • Active debt reduction demonstrates disciplined capital allocation and strengthening of the balance sheet over time
  • TTM sales growth of 32% shows continued momentum in the most recent period with no signs of deceleration from the 3-year trend
  • Operating in the chronic kidney disease treatment space which has structural tailwinds from rising diabetes and hypertension prevalence in India
  • TTM profit growth of 12% shows the company remains profitable and growing even as it scales, though at a slower pace than historical averages
Bear Case 8
  • PE ratio of 89.4x is extremely elevated, pricing in significant future growth and leaving little margin of safety if execution falters
  • 3-year average ROE of only 10% is modest for a company trading at such premium valuations, suggesting capital is not being deployed efficiently enough to justify the price
  • Zero dividend yield despite repeated profitability indicates shareholders receive no income return, with all value dependent on capital appreciation
  • Price-to-book ratio of 6.15x means investors are paying a steep premium over the company's net asset value
  • TTM profit growth has decelerated sharply to 12% compared to 103% CAGR over 3 years, suggesting growth normalization or margin pressure
  • Company's cost of borrowing appears high, which could erode returns if any future debt is taken on for expansion
  • Last year ROE of 9% is below the 3-year average of 10%, indicating a declining trend in return on equity rather than improvement
  • With no stock CAGR data available across any time period, there is limited price history transparency for investors to assess historical shareholder returns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Neutral 3
  • Rs 70 Cr block trade executed Jul 9

    A block trade worth Rs 70 crore was executed on NSE/BSE for approximately 11 lakh shares at Rs 636.36 per share, indicating significant large-scale institutional activity.

  • Q1FY27 earnings call Aug 12 Jul 24

    Nephrocare has scheduled its Q1FY27 earnings conference call for August 12, 2026 to discuss unaudited standalone and consolidated results for the quarter ended June 30, 2026.

  • 17th AGM on Aug 12 Jul 17

    Nephrocare will hold its 17th AGM on August 12, 2026 via video conferencing, with remote e-voting open from August 8 to August 11.

TL;DR: A quiet period for Nephrocare Health Services with no material positive or negative catalysts. The Rs 70 crore block trade suggests institutional interest but direction is unclear without knowing buyer/seller intent. Investors should watch the Q1FY27 results on Aug 12 for growth trajectory and margin trends in the dialysis services business.

Quarterly Results

Particulars Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
197
219
228
246
260
266
282
Expenses
153
168
180
182
199
215
221
Operating Profit
44
51
48
64
61
51
60
OPM %
22%
23%
21%
26%
23%
19%
21%
Other Income
5
4
7
4
3
12
7
Interest
5
6
6
45
6
3
2
Depreciation
18
19
20
23
22
26
25
PBT
26
30
29
-1
36
33
41
Tax %
24%
17%
17%
1427%
11%
9%
22%
Net Profit
20
25
24
-9
32
30
32
EPS in Rs
96.5
119
13.1
-5.24
3.21
3.03
3.19
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
286
318
437
566
756
999
1,053
Expenses
248
302
389
465
589
774
817
Operating Profit
37
16
49
101
167
225
236
OPM %
13%
5%
11%
18%
22%
23%
22%
Other Income
5
10
6
8
14
23
26
Interest
7
10
16
20
21
60
56
Depreciation
34
42
47
56
72
91
96
PBT
1
-27
-9
33
87
97
110
Tax %
31%
-21%
37%
-6%
23%
21%
—
Net Profit
1
-21
-12
35
67
77
85
EPS in Rs
3.4
-107
-58.69
170
322
7.66
4.19
Div. Payout %
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
2
2
2
20
Reserves
245
391
384
409
579
1,096
Borrowings
140
119
200
271
261
80
Other Liabilities
42
59
81
124
153
271
Total Liabilities
428
571
666
806
994
1,467
Fixed Assets
192
205
239
356
396
517
CWIP
2
43
34
1
6
6
Investments
0
0
0
0
51
178
Other Assets
234
322
393
449
542
767
Total Assets
428
571
666
806
994
1,467
Figures in ₹ Crores

Cash Flow

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
32
14
11
72
135
233
Investing
-62
-130
-76
-52
-125
-392
Financing
36
121
60
27
54
157
Net Cash Flow
5
6
-4
47
65
-2
Free Cash Flow
-29
-64
-62
-8
35
113
CFO/OP
49
119
14
80
82
116
Figures in ₹ Crores

Ratios

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
101
123
132
131
129
116
Inventory Days
65
50
67
—
—
—
Days Payable
56
70
63
—
—
—
Cash Conversion Cycle
110
103
137
131
129
116
Working Capital Days
26
55
19
56
27
42
ROCE %
—
-4%
1%
8%
14%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Nephrocare Health Services insights

55 extracted metrics + investor summaries across FY21–FY26.

Log in — free

Shareholding Pattern

Public5.70%Promot.63.85%FIIs8.78%DIIs9.05%Others12.62%As ofJun 2026

Documents

Frequently Asked Questions about Nephrocare Health Services

What does Nephrocare Health Services Ltd do?
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
Where is Nephrocare Health Services Ltd (NEPHROPLUS) listed?
Nephrocare Health Services Ltd trades as NEPHROPLUS on the NSE and under code 544647 on the BSE.
Which sector does Nephrocare Health Services Ltd belong to?
Nephrocare Health Services Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd has a market capitalisation of ₹7,489 Cr, which places it in the Mid Cap band.
What is the PE ratio of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd trades at a PE ratio of 182.66, against a book value of ₹111.03 per share.
What is the 52-week high and low of Nephrocare Health Services Ltd?
Over the last 52 weeks Nephrocare Health Services Ltd has traded between ₹446 and ₹769.75.
What is the Return on Equity (ROE) of Nephrocare Health Services Ltd?
Nephrocare Health Services Ltd reported a return on equity of 6.88%. Its debt-to-equity ratio is 0.07.

Company Information

Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]

Website nephroplus.com
Listed 2025-12-17
Face Value ₹ 2
Issued Size 10,03,40,717

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NEPHROPLUS.md for Nephrocare Health Services Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare Services → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List